The efficacy of tucatinib

Final results from the main study of tucatinib, presented by Clinicians, show how long patients overall survived on the drug and how long their disease did not worsen. Tucatinibhas been shown to prolong survival in patients with advanced or metastaticHER2-positive breast cancer without worsening the disease and subsequently in combination with trastuzumabin adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer.

In a major ongoing study of 612 patients whose disease worsened after previous treatment or who were not suitable for other treatments, tucatinib was compared with placebo when two other cancer drugs, trastuzumab and capecitabine, were added. When the results were analyzed, patients in the tucatinib group lived an average of 7.8 months without disease progression. About 41% of patients who received tucatinib had some response to the treatment, and patients lived an average of 22 months. In a subgroup of patients whose cancer had spread to the brain, responses to tucatinib were comparable.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug sold overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of tucatinib produced in other countries. The price of Tucatinib produced by a Lao pharmaceutical factory is around 6,400 yuan (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.